β-cell-specific glucocorticoid reactivation attenuates inflammatory β-cell destruction

Xiaoxia Liu, Sophie Turban, Roderick N. Carter, Shakil Ahmad, Lynne Ramage, Scott P. Webster, Brian R. Walker, Jonathan R. Seckl, Nicholas M. Morton

Research output: Contribution to journalArticle

Abstract

Progression and severity of type 1 diabetes is dependent upon inflammatory induction of nitric oxide production and consequent pancreatic β-cell damage. Glucocorticoids (GCs) are highly effective anti-inflammatory agents but have been precluded in type 1 diabetes and in islet transplantation protocols because they exacerbated insulin resistance and suppressed β-cell insulin secretion at the high-doses employed clinically. In contrast, physiological-range elevation of GC action within β-cells ameliorated lipotoxic β-cell failure in transgenic mice overexpressing the intracellular enzyme 11β-hydroxysteroid dehydrogenase type 1 (MIP-HSD1<sup>tg/+</sup> mice). Here, we tested the hypothesis that elevated β-cell 11beta-HSD1 protects against the β-cell destruction elicited by streptozotocin (STZ), a toxin that dose-dependently mimics aspects of inflammatory and autoimmune β-cell destruction. MIP-HSD1<sup>tg/+</sup> mice exhibited an episodic protection from the severe hyperglycemia caused by a single high dose of STZ associated with higher and sustained β-cell survival, maintained β-cell replicative potential, higher plasma and islet insulin levels, reduced inflammatory macrophage infiltration and increased anti-inflammatory T regulatory cell content. MIP-HSD1<sup>tg/+</sup> mice also completely resisted mild hyperglycemia and insulitis induced by multiple low-dose STZ administration. In vitro, MIP-HSD1<sup>tg/+</sup> islets exhibited attenuated STZ-induced nitric oxide production, an effect reversed with a specific 11beta-HSD1 inhibitor. GC regeneration selectively within β-cells protects against inflammatory β-cell destruction, suggesting therapeutic targeting of 11beta-HSD1 may ameliorate processes that exacerbate type 1 diabetes and that hinder islet transplantation.

Original languageEnglish
Article number165
Number of pages7
JournalFrontiers in Endocrinology
Volume5
DOIs
Publication statusPublished - 11 Oct 2014

Fingerprint

Glucocorticoids
11-beta-Hydroxysteroid Dehydrogenase Type 1
Streptozocin
Type 1 Diabetes Mellitus
Islets of Langerhans Transplantation
Hyperglycemia
Nitric Oxide
Anti-Inflammatory Agents
11-beta-Hydroxysteroid Dehydrogenases
Insulin
Transgenic Mice
Insulin Resistance
Regeneration
Cell Survival
Macrophages
Enzymes

Bibliographical note

© 2014 Liu, Turban, Carter, Ahmad, Ramage, Webster, Walker, Seckl and Morton. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Funding: China Overseas Scholarship and Research Councils UK Fellowship.

Supplementary Material: http://www.frontiersin.org/Journal/10.3389/fendo.2014.00165/abstract

Keywords

  • 11beta-hydrosteroid dehydrogenase type 1
  • anti-inflammatory agents
  • beta-cells
  • glucocorticoids
  • inflammation
  • insulin secretion
  • streptozotocin
  • type 1 diabetes

Cite this

Liu, Xiaoxia ; Turban, Sophie ; Carter, Roderick N. ; Ahmad, Shakil ; Ramage, Lynne ; Webster, Scott P. ; Walker, Brian R. ; Seckl, Jonathan R. ; Morton, Nicholas M. / β-cell-specific glucocorticoid reactivation attenuates inflammatory β-cell destruction. In: Frontiers in Endocrinology. 2014 ; Vol. 5.
@article{ee4d523ff4fa4270bd82b942eaa97c6b,
title = "β-cell-specific glucocorticoid reactivation attenuates inflammatory β-cell destruction",
abstract = "Progression and severity of type 1 diabetes is dependent upon inflammatory induction of nitric oxide production and consequent pancreatic β-cell damage. Glucocorticoids (GCs) are highly effective anti-inflammatory agents but have been precluded in type 1 diabetes and in islet transplantation protocols because they exacerbated insulin resistance and suppressed β-cell insulin secretion at the high-doses employed clinically. In contrast, physiological-range elevation of GC action within β-cells ameliorated lipotoxic β-cell failure in transgenic mice overexpressing the intracellular enzyme 11β-hydroxysteroid dehydrogenase type 1 (MIP-HSD1tg/+ mice). Here, we tested the hypothesis that elevated β-cell 11beta-HSD1 protects against the β-cell destruction elicited by streptozotocin (STZ), a toxin that dose-dependently mimics aspects of inflammatory and autoimmune β-cell destruction. MIP-HSD1tg/+ mice exhibited an episodic protection from the severe hyperglycemia caused by a single high dose of STZ associated with higher and sustained β-cell survival, maintained β-cell replicative potential, higher plasma and islet insulin levels, reduced inflammatory macrophage infiltration and increased anti-inflammatory T regulatory cell content. MIP-HSD1tg/+ mice also completely resisted mild hyperglycemia and insulitis induced by multiple low-dose STZ administration. In vitro, MIP-HSD1tg/+ islets exhibited attenuated STZ-induced nitric oxide production, an effect reversed with a specific 11beta-HSD1 inhibitor. GC regeneration selectively within β-cells protects against inflammatory β-cell destruction, suggesting therapeutic targeting of 11beta-HSD1 may ameliorate processes that exacerbate type 1 diabetes and that hinder islet transplantation.",
keywords = "11beta-hydrosteroid dehydrogenase type 1, anti-inflammatory agents, beta-cells, glucocorticoids, inflammation, insulin secretion, streptozotocin, type 1 diabetes",
author = "Xiaoxia Liu and Sophie Turban and Carter, {Roderick N.} and Shakil Ahmad and Lynne Ramage and Webster, {Scott P.} and Walker, {Brian R.} and Seckl, {Jonathan R.} and Morton, {Nicholas M.}",
note = "{\circledC} 2014 Liu, Turban, Carter, Ahmad, Ramage, Webster, Walker, Seckl and Morton. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Funding: China Overseas Scholarship and Research Councils UK Fellowship. Supplementary Material: http://www.frontiersin.org/Journal/10.3389/fendo.2014.00165/abstract",
year = "2014",
month = "10",
day = "11",
doi = "10.3389/fendo.2014.00165",
language = "English",
volume = "5",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S.A.",

}

Liu, X, Turban, S, Carter, RN, Ahmad, S, Ramage, L, Webster, SP, Walker, BR, Seckl, JR & Morton, NM 2014, 'β-cell-specific glucocorticoid reactivation attenuates inflammatory β-cell destruction', Frontiers in Endocrinology, vol. 5, 165. https://doi.org/10.3389/fendo.2014.00165

β-cell-specific glucocorticoid reactivation attenuates inflammatory β-cell destruction. / Liu, Xiaoxia; Turban, Sophie; Carter, Roderick N.; Ahmad, Shakil; Ramage, Lynne; Webster, Scott P.; Walker, Brian R.; Seckl, Jonathan R.; Morton, Nicholas M.

In: Frontiers in Endocrinology, Vol. 5, 165, 11.10.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - β-cell-specific glucocorticoid reactivation attenuates inflammatory β-cell destruction

AU - Liu, Xiaoxia

AU - Turban, Sophie

AU - Carter, Roderick N.

AU - Ahmad, Shakil

AU - Ramage, Lynne

AU - Webster, Scott P.

AU - Walker, Brian R.

AU - Seckl, Jonathan R.

AU - Morton, Nicholas M.

N1 - © 2014 Liu, Turban, Carter, Ahmad, Ramage, Webster, Walker, Seckl and Morton. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Funding: China Overseas Scholarship and Research Councils UK Fellowship. Supplementary Material: http://www.frontiersin.org/Journal/10.3389/fendo.2014.00165/abstract

PY - 2014/10/11

Y1 - 2014/10/11

N2 - Progression and severity of type 1 diabetes is dependent upon inflammatory induction of nitric oxide production and consequent pancreatic β-cell damage. Glucocorticoids (GCs) are highly effective anti-inflammatory agents but have been precluded in type 1 diabetes and in islet transplantation protocols because they exacerbated insulin resistance and suppressed β-cell insulin secretion at the high-doses employed clinically. In contrast, physiological-range elevation of GC action within β-cells ameliorated lipotoxic β-cell failure in transgenic mice overexpressing the intracellular enzyme 11β-hydroxysteroid dehydrogenase type 1 (MIP-HSD1tg/+ mice). Here, we tested the hypothesis that elevated β-cell 11beta-HSD1 protects against the β-cell destruction elicited by streptozotocin (STZ), a toxin that dose-dependently mimics aspects of inflammatory and autoimmune β-cell destruction. MIP-HSD1tg/+ mice exhibited an episodic protection from the severe hyperglycemia caused by a single high dose of STZ associated with higher and sustained β-cell survival, maintained β-cell replicative potential, higher plasma and islet insulin levels, reduced inflammatory macrophage infiltration and increased anti-inflammatory T regulatory cell content. MIP-HSD1tg/+ mice also completely resisted mild hyperglycemia and insulitis induced by multiple low-dose STZ administration. In vitro, MIP-HSD1tg/+ islets exhibited attenuated STZ-induced nitric oxide production, an effect reversed with a specific 11beta-HSD1 inhibitor. GC regeneration selectively within β-cells protects against inflammatory β-cell destruction, suggesting therapeutic targeting of 11beta-HSD1 may ameliorate processes that exacerbate type 1 diabetes and that hinder islet transplantation.

AB - Progression and severity of type 1 diabetes is dependent upon inflammatory induction of nitric oxide production and consequent pancreatic β-cell damage. Glucocorticoids (GCs) are highly effective anti-inflammatory agents but have been precluded in type 1 diabetes and in islet transplantation protocols because they exacerbated insulin resistance and suppressed β-cell insulin secretion at the high-doses employed clinically. In contrast, physiological-range elevation of GC action within β-cells ameliorated lipotoxic β-cell failure in transgenic mice overexpressing the intracellular enzyme 11β-hydroxysteroid dehydrogenase type 1 (MIP-HSD1tg/+ mice). Here, we tested the hypothesis that elevated β-cell 11beta-HSD1 protects against the β-cell destruction elicited by streptozotocin (STZ), a toxin that dose-dependently mimics aspects of inflammatory and autoimmune β-cell destruction. MIP-HSD1tg/+ mice exhibited an episodic protection from the severe hyperglycemia caused by a single high dose of STZ associated with higher and sustained β-cell survival, maintained β-cell replicative potential, higher plasma and islet insulin levels, reduced inflammatory macrophage infiltration and increased anti-inflammatory T regulatory cell content. MIP-HSD1tg/+ mice also completely resisted mild hyperglycemia and insulitis induced by multiple low-dose STZ administration. In vitro, MIP-HSD1tg/+ islets exhibited attenuated STZ-induced nitric oxide production, an effect reversed with a specific 11beta-HSD1 inhibitor. GC regeneration selectively within β-cells protects against inflammatory β-cell destruction, suggesting therapeutic targeting of 11beta-HSD1 may ameliorate processes that exacerbate type 1 diabetes and that hinder islet transplantation.

KW - 11beta-hydrosteroid dehydrogenase type 1

KW - anti-inflammatory agents

KW - beta-cells

KW - glucocorticoids

KW - inflammation

KW - insulin secretion

KW - streptozotocin

KW - type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84930683381&partnerID=8YFLogxK

U2 - 10.3389/fendo.2014.00165

DO - 10.3389/fendo.2014.00165

M3 - Article

VL - 5

JO - Frontiers in Endocrinology

JF - Frontiers in Endocrinology

SN - 1664-2392

M1 - 165

ER -